The Copaxone News Channel

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business.

#1 Glaterimer acetate Teva $4.3 billion
#2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

sorry: this post was late due to technical problems! Friday's news will be posted at our normal time: midnight

Thursday's News for Neurologists: Here's 208 New Studies from 10/1 to Thursday 10/24:

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Results confirm a favourable effect on relapses as pregnancy proceeds, and an early postpartum peak. Pre-conception DMT exposure and low ARR were independently protective against postpartum relapse. This novel finding could provide clinicians with a strategy to minimise postpartum relapse risk in women with MS planning pregnancy.

Younger age, female sex, and high number of awakenings and arousals predict fatigue in patients with sleep disorders: a retrospective polysomnographic observational study.

Younger age, female sex, and high number of awakenings and arousals are predictive of fatigue in sleep-disordered patients. Further investigations are needed to find the pathophysiological explanation for these relationships.

Copaxone (Glatiramer acetate) treatment effects on gene expression in monocytes of multiple sclerosis patients.
Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular mechanisms of GA therapy.

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Most MS patients initiating DMT started on platform therapy. Natalizumab initiators tended to stay on index therapy, have fewer treatment gaps, and switch less than platform initiators in the 2 years after treatment initiation. Switching between platform therapies is common despite evidence that MS patients on platform therapy may benefit from switching to natalizumab.

[Cavitary lesions in multiple sclerosis: Multicenter study on twenty patients.]
MS patients with large cavitary lesions seem to represent a MS subgroup, predominantly women, with relatively late disease onset, predominantly primary-progressive type, relatively high EDSS scores, and severe cognitive dysfunction.

Read more »

Labels: Ampyra, Gilenya, sativex, Tysabri

Click Here For My Videos, Advice, Tips, Studies and Trials.

Timothy L. Vollmer, MD

Click here to read my columns

Brian R. Apatoff, MD, PhD

Friday

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

"Researchers don’t know why some multiple sclerosis therapies work"

Thursday

"RESEARCHERS DON'T KNOW WHY SOME MS TREATMENTS WORK"

Researchers don’t know why some multiple sclerosis therapies work

Sunday

Friday's News for Neurologists: Here's 276 New Studies from 10/1 to Friday 11/1

Thursday's News for Neurologists: Here's 266 New Studies from 10/1 to Thursday 10/31

Tuesday's News for Neurologists: Here's 256 New Studies from 10/1 to Tuesday 10/29:

sorry: this post was late due to technical problems! Friday's news will be posted at our normal time: midnight